美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Astellas Pharma, Inc.

15.09

-0.3400-2.20%

成交量：3,849.00

成交額：5.80萬

市值：270.16億

市盈率：202.95

高：15.31

開：15.00

低：14.93

收：15.43

52周最高：17.35

52周最低：8.97

股本：17.90億

流通股本：17.45億

量比：0.30

換手率：0.00%

股息：0.51

股息率：3.40%

每股收益(TTM):0.0744

每股收益(LYR):0.0628

淨資產收益率：19.82%

總資產收益率：7.38%

市淨率：2.44

市盈率(LYR):240.13

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

安斯泰來製藥：FDA根據《處方藥使用者費用法案》設定2026年8月17日為關鍵審批日期

安斯泰來：EV-304研究中圍術期enfortumab vedotin聯合帕博利珠單抗的安全性特徵與既往聯合用藥經驗一致

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ALPMY"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALPMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","market":"US","secType":"STK","nameCN":"Astellas Pharma, Inc.","latestPrice":15.09,"timestamp":1777298400000,"preClose":15.43,"halted":0,"volume":3849,"delay":15,"changeRate":-0.02203499675955929,"floatShares":1745183156,"shares":1790310070,"eps":0.074352,"marketStatus":"交易中","change":-0.34,"latestTime":"04-27 10:00:00 EDT 延時","open":15,"high":15.31,"low":14.9316,"amount":58005.526965,"amplitude":0.024524,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.074352,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1777320000000},"marketStatusCode":2,"adr":0,"adrRate":1,"exchange":"PINK LIMITED","adjPreClose":15.43,"volumeRatio":0.301728},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","floatShares":1745183156,"roa":"7.38%","roe":"19.82%","lyrEps":0.062841,"volumeRatio":0.301728,"shares":1790310070,"dividePrice":0.5124,"high":15.31,"amplitude":0.024524,"preClose":15.43,"low":14.9316,"week52Low":8.97,"pbRate":"2.44","psRate":"2.09","week52High":17.35,"institutionHeld":0,"latestPrice":15.09,"eps":0.074352,"divideRate":0.033956,"volume":3849,"delay":15,"ttmEps":0.074352,"open":15,"prevYearClose":13.29,"prevWeekClose":15.43,"prevMonthClose":16.22,"prevQuarterClose":16.22,"fiveDayClose":16.18,"twentyDayClose":16.09,"sixtyDayClose":13.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALPMY\",params:#limit:5,,,undefined,":[{"date":"2026-04-27","symbol":"ALPMY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1777276800000,"name":null,"time":"","dateTimestamp":1777262400000,"actualEps":null},{"market":"US","date":"2025-02-04","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"","actualEps":null},{"date":"2024-08-01","symbol":"ALPMY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722499200000,"name":null,"time":"","dateTimestamp":1722484800000,"actualEps":null},{"market":"US","date":"2024-04-25","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-02-05","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1707109200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALPMY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALPMY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1758254400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALPMY\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1159770601","title":"安斯泰來製藥：FDA根據《處方藥使用者費用法案》設定2026年8月17日為關鍵審批日期","url":"https://stock-news.laohu8.com/highlight/detail?id=1159770601","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159770601?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 18:48","pubTimestamp":1776682090,"startTime":"0","endTime":"0","summary":"根据《处方药使用者费用法案》框架，美国食品药品监督管理局已为安斯泰来制药的核心新药申请划定重要时间节点——2026年8月17日被正式确立为监管审评的目标行动日期。这一关键时间点的设定，标志着该创新疗法的审评进程进入倒计时阶段，为市场预期提供了明确的时间坐标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225771236.USD","LU0234572021.USD","LU0306807586.USD","ALPMF","LU0306806265.USD","LU1057294990.SGD","ALPMY","LU1894683348.USD","LU0985481810.HKD","SGXZ57979304.SGD","LU1066051498.USD","LU0868494617.USD","LU0321505868.SGD","SG9999001176.USD","LU1894683264.USD","BK4533","IE00B19Z3B42.SGD","SG9999001176.SGD","SG9999011175.SGD","BK4534","SG9999013999.USD","IE00BLSP4239.USD","BK4585","IE00BLSP4452.SGD","LU0289739699.SGD","LU0456855351.SGD","BK4568","LU0225284248.USD","BK4550","LU0122379950.USD","BK4588","LU1023059063.AUD","BK4007","SG9999003800.SGD","IE00B19Z3581.USD","IE000M9KFDE8.USD","SG9999002224.SGD","LU0058720904.USD","SG9999002232.USD","IE00BBT3K403.USD","IE0002270589.USD","LU0321505439.SGD","LU1883839398.USD","BK4581","LU0170899867.USD","LU1066053197.SGD","BK4592","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164144381","title":"安斯泰來：EV-304研究中圍術期enfortumab vedotin聯合帕博利珠單抗的安全性特徵與既往聯合用藥經驗一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1164144381","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164144381?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 23:05","pubTimestamp":1772204701,"startTime":"0","endTime":"0","summary":"根据EV-304研究数据，安斯泰来制药公司公布的最新结果显示，在围术期使用enfortumab vedotin联合帕博利珠单抗的治疗方案，其安全性特征与先前对该联合疗法的经验保持一致。\n这一发现进一步支持了该联合治疗方案在临床应用中的安全性一致性，为后续治疗策略的制定提供了重要参考依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0321505439.SGD","LU1066051498.USD","SG9999003800.SGD","SG9999001176.SGD","LU0868494617.USD","BK4007","SG9999001176.USD","LU0225284248.USD","LU0234572021.USD","BK4592","BK4534","LU0170899867.USD","LU0306807586.USD","IE0002270589.USD","LU1894683264.USD","SG9999011175.SGD","LU1883839398.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","BK4568","LU0289739699.SGD","LU1894683348.USD","IE00BLSP4452.SGD","SG9999002224.SGD","SG9999002232.USD","SGXZ57979304.SGD","LU0985481810.HKD","IE000M9KFDE8.USD","LU0321505868.SGD","LU0122379950.USD","LU0456855351.SGD","BK4581","LU0225771236.USD","BK4588","LU1023059063.AUD","ALPMY","BK4585","IE00BLSP4239.USD","LU0058720904.USD","BK4533","LU1057294990.SGD","IE00B19Z3581.USD","IE00BBT3K403.USD","BK4599","SG9999013999.USD","LU0306806265.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ALPMY\",params:#limit:6,delay:false,,,undefined,":[]}}